menu
    • menu
    [{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Lotus Pharmaceutical","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Actavis Inc

    Menu

    Actavis Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia

                            Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.

                            Product Name : LNZ100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 09, 2025

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth